Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2010-04-01
2011-10-11
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S001410, C424S001490, C424S133100, C424S134100, C424S143100, C424S145100, C424S152100, C424S153100, C424S155100, C424S178100, C424S179100, C424S192100, C530S388230, C530S391100, C530S391300, C530S391700, C514S021300, C514S007700
Reexamination Certificate
active
08034352
ABSTRACT:
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b.
REFERENCES:
patent: 4046722 (1977-09-01), Rowland
patent: 4699784 (1987-10-01), Shih et al.
patent: 4868109 (1989-09-01), Lansdorp et al.
patent: 5770198 (1998-06-01), Coller et al.
patent: 6261537 (2001-07-01), Klaveness et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6524854 (2003-02-01), Monia et al.
patent: 6617135 (2003-09-01), Gillies et al.
patent: 7060506 (2006-06-01), Craig
patent: 7151164 (2006-12-01), Hansen et al.
patent: 7521056 (2009-04-01), Chang et al.
patent: 7527787 (2009-05-01), Chang et al.
patent: 7534866 (2009-05-01), Chang et al.
patent: 7541440 (2009-06-01), Goldenberg et al.
patent: 7550143 (2009-06-01), Chang et al.
patent: 7591994 (2009-09-01), Govindan et al.
patent: 7666400 (2010-02-01), Chang et al.
patent: 7858070 (2010-12-01), Chang et al.
patent: 7871622 (2011-01-01), Chang et al.
patent: 7901680 (2011-03-01), Chang et al.
patent: 7902338 (2011-03-01), Hansen et al.
patent: 7906118 (2011-03-01), Chang et al.
patent: 7906121 (2011-03-01), Chang et al.
patent: 7919273 (2011-04-01), Goldenberg et al.
patent: 2003/0198956 (2003-10-01), Makowski et al.
patent: 2003/0232420 (2003-12-01), Braun et al.
patent: 2004/0018587 (2004-01-01), Makowski et al.
patent: 2005/0003403 (2005-01-01), Rossi et al.
patent: 2006/0210475 (2006-09-01), Goldenberg et al.
patent: 2007/0020259 (2007-01-01), Hansen et al.
patent: 2007/0264265 (2007-11-01), Goldenberg et al.
patent: 2009/0060862 (2009-03-01), Chang et al.
patent: 2009/0111143 (2009-04-01), Goldenberg et al.
patent: 2009/0202487 (2009-08-01), Chang et al.
patent: 2010/0189689 (2010-07-01), Chang et al.
patent: 2011/0020273 (2011-01-01), Chang et al.
patent: 2000/068248 (2000-11-01), None
patent: 2006/107617 (2006-10-01), None
patent: 2006/107786 (2006-10-01), None
patent: WO 2007/046893 (2007-04-01), None
patent: 2007/075270 (2007-07-01), None
patent: 2008/033413 (2008-03-01), None
Zhu et al, Investigational New Drugs 17: 195-212, 1999.
Stancoviski et al, Proceedings of the National Academy of Science USA 88: 8691-8695, 1991.
Riemer et al, Mol. lmmunol. 42: 1121-1124, 2005.
Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Comp. 1991, p. 43.
Alto et al., “Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring”, Proc. Natl. Acad. Sci USA Apr. 15, 2003: 100(8):4445-50.
Backer et al., “Self-Assembled “Dock and Lock” System for Linking Payloads to Targeting Proteins”, Bioconjugate Chem., 2006, 17(4):912-919.
Baillie et al., “Compartmentalisation of phospodiesterases and protein kinase A: opposites attract”, FEBS Letters 2005; 579:3264-3270.
Banky et al., “Dimerization/Docking Domain of the Type Iα Regulatory Subunit of cAMP-dependent Protein Kinase”, J. Biol. Chem. 273:35048-55, 1998.
Basu et al., “Structure-Function Engineering of Interferon-β-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation”, Bioconjugate Chem. 2006; 17:618-630.
Belardelli et al., “Interferon-alpha in tumor immunity and immunotherapy”, Cytokine Growth Factor Rev. 13 (2):119-134 (2002).
Belardelli et al., “International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?”, Cancer Res. 64:6827-6830 (2004).
Belardelli and Gresser, “The neglected role of type I interferon in the T-cell response: implications for its clinical use”, Immunol. Today 17(8):369-72 (1996).
Biron et al., “Natural killer cells in antiviral defense: function and regulation by innate cytokines”, Annu. Rev. Immunol. 17:189-220 (1999).
Brunda et al., “Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons”, Cancer Res. 44:597-601 (1984).
Burns-Hamuro et al., “Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange”, Protein Science (2005), 14:2982-2992.
Carr et al., “Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif”, J. Biol. Chem. 266:14188-92 (1991).
Carr et al., “Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA”, J. Biol. Chem. 276(20):17332-17338 (2001).
Carrero et al., “Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes”, J. Exp. Med. 203(4):933-940 (2006).
Chang et al., “The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity”, Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.
Chmura et al., “Antibodies with infinite affinity”, Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001).
Colledge et al., “AKAPs: from structure to function”, Trends Cell Biol. 6:216-21 (1999).
Corbin et al., “Regulation of Adenosine 3′,5′-Monophosphate-dependent Protein Kinase”, J. Biol. Chem. 248:1813-21 (1973).
Dhalluin et al., “Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-α2a and Its Individual Positional Isomers”, Bioconjugate Chem. 2005;16:504-517.
Dodart et al., “Immunotherapy for Alzheimer's Disease: will vaccination work?”, Trends Mol. Med. 9(3):85-87 (2003).
Doherty et al., “Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor”, Bioconjugate Chem. 2005;16:1291-1298.
Ferrantini et al., “IFN-α1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity”, J. Immunol. 153:4604-15 (1994).
Ferrantini et al., “Interferon-α and cancer: Mechanisms of action and new perspectives of clinical use”, Biochimie 89: 884-893 (2007).
Gillies et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes”, J. Immunol. Methods 125 (1989) 191-202.
Glennie et al., “Mechanisms of killing by anti-CD20 monoclonal antibodies”, Mol. Immunol. 44:3823-3837 (2007).
Gold et al., “A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma”, Cancer Res. 68:4819-26, 2008.
Gold et al., “Molecular Basis of AKAP Specificity for PKA Regulatory Subunits”, Mol. Cell Nov. 3, 2006;24(3):383-95.
Goldenberg et al., “Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting”, J. Nucl. Med. 49:158-63, 2008.
Goldenberg et al., “Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody”, Blood 113:1062-70 (2009).
Goodson a
Chang Chien-Hsing
Goldenberg David M.
Rossi Edmund A.
Huynh Phuong
IBC Pharmaceuticals, Inc.
Nakashima Richard A.
LandOfFree
Tetrameric cytokines with improved biological activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrameric cytokines with improved biological activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrameric cytokines with improved biological activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4269105